VALENCIA, Calif.--(BUSINESS WIRE)--Bioness, Inc. announced today that the first commercial procedure of StimRouter™ Neuromodulation System has been performed under the company’s FDA clearance to treat chronic, intractable pain of peripheral nerve origin as an adjunct to other modes of therapy. StimRouter is the only implantable neuromodulation device indicated and marketed to treat chronic pain of peripheral nerve origin.
Help employers find you! Check out all the jobs and post your resume.
